neuroClues is ISO27001:2022 certified ensuring the security of patient & hospital data
Since April 3rd 2026 neuroClues is certified ISO27001:2022 for Information Security Management Systems by AFNOR. This ce …
neuroClues® raises a Series A of 10M€ to accelerate its commercialization
Brussels & Paris, March 31, 2026 – Months after receiving CE certification for its Class IIa medical device, neuroCl …
Join the Adventure: Become a neuroClues Shareholder
Brussels, 27 January 2026 — Today, we at P3lab (doing business as neuroClues) are launching our crowdfunding campaign on …
Concussion Assessment and Monitoring with Eye Movement Biomarkers
Clinical highlights – November 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, av …
Instability of Neurological Diagnosis
Clinical highlights – June 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, availa …
Reliability of Oculomotor Biomarkers
Clinical highlights – May 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, availab …
Exploring Antisaccades and Frontal Lobe Function
Clinical highlights – April 2025 neuroClues has officially received its CE-marking as a Class IIa medical device, availa …
Neural Pathways of Voluntary and Reflexive Saccades
Clinical highlights – March 2025 In this article, we explore the differences between voluntary and reflexive saccades, t …
Oculomotor Biomarkers Recorded on 50 Patients with neuroClues®, now CE-Marked!
Clinical highlights – February 2025 This month’s newsletter is eye-opening. As you may know, neuroClues® has officially …
.png)
